- Home
- NYXH vs INBX Comparison
NYXH vs INBX Comparison
Compare NYXH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- INBX
- Stock Information
- Founded
- NYXH 2009
- INBX 2010
- Country
- NYXH Belgium
- INBX United States
- Employees
- NYXH N/A
- INBX N/A
- Industry
- NYXH Medical/Dental Instruments
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- NYXH Health Care
- INBX Health Care
- Exchange
- NYXH Nasdaq
- INBX Nasdaq
- Market Cap
- NYXH 222.3M
- INBX 178.5M
- IPO Year
- NYXH 2021
- INBX 2020
- Fundamental
- Price
- NYXH $5.78
- INBX $11.28
- Analyst Decision
- NYXH Strong Buy
- INBX Hold
- Analyst Count
- NYXH 4
- INBX 1
- Target Price
- NYXH $14.50
- INBX N/A
- AVG Volume (30 Days)
- NYXH 117.0K
- INBX 94.2K
- Earning Date
- NYXH 05-14-2025
- INBX 05-20-2025
- Dividend Yield
- NYXH N/A
- INBX 7.45%
- EPS Growth
- NYXH N/A
- INBX N/A
- EPS
- NYXH N/A
- INBX 112.62
- Revenue
- NYXH $4,680,609.00
- INBX $200,000.00
- Revenue This Year
- NYXH $323.07
- INBX N/A
- Revenue Next Year
- NYXH $204.30
- INBX N/A
- P/E Ratio
- NYXH N/A
- INBX $0.10
- Revenue Growth
- NYXH 3.98
- INBX N/A
- 52 Week Low
- NYXH $5.55
- INBX $10.80
- 52 Week High
- NYXH $12.21
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- NYXH 34.87
- INBX 41.19
- Support Level
- NYXH $6.03
- INBX $10.90
- Resistance Level
- NYXH $6.66
- INBX $11.98
- Average True Range (ATR)
- NYXH 0.33
- INBX 0.85
- MACD
- NYXH 0.11
- INBX -0.02
- Stochastic Oscillator
- NYXH 15.38
- INBX 19.75
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.